Skip to main content
. 2023 May 16;20:116. doi: 10.1186/s12974-023-02802-0

Fig. 5.

Fig. 5

miRNAs that target autophagy and dopamine metabolism are significantly altered between placebo and nilotinib. A total of 17 microRNAs (1.6%) were significantly different between the placebo and nilotinib groups, accounting for both treatment and time. Ingenuity Pathway Analysis of microRNA matched associated mRNAs or targets that are experimentally validated from TarBase, miRecords, as well as highly predicted miRNA–mRNA interactions from TargetScan and revealed that 14 of these microRNAs are associated with genes that control autophagy and dopamine metabolism. N = 11 placebo, n = 12 nilotinib